What is Zacks Research's Estimate for GSK FY2026 Earnings?

Key Points

• Analysts at Zacks Research have raised their FY2026 earnings per share (EPS) estimate for GSK to $4.74, up from $4.70, reflecting positive expectations for the pharmaceutical company.
• GSK's quarterly earnings exceeded expectations, reporting an EPS of $1.23 against a consensus estimate of $1.12, accompanied by a quarterly revenue of $10.64 billion.
• The company is set to pay a quarterly dividend of $0.4206 per share, resulting in an annualized dividend yield of 4.3%, with a payout ratio of 77.78%.

GSK PLC Sponsored ADR (NYSE:GSK - Free Report) - Investment analysts at Zacks Research lifted their FY2026 earnings per share estimates for GSK in a research report issued to clients and investors on Tuesday, September 2nd. Zacks Research analyst Team now forecasts that the pharmaceutical company will post earnings of $4.74 per share for the year, up from their previous forecast of $4.70. The consensus estimate for GSK's current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK's FY2027 earnings at $4.78 EPS.

A number of other research firms have also issued reports on GSK. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Stock Performance

Shares of GSK traded up $0.80 during mid-day trading on Friday, hitting $40.41. The stock had a trading volume of 6,540,596 shares, compared to its average volume of 3,230,991. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. GSK has a 52 week low of $31.72 and a 52 week high of $44.19. The firm has a market cap of $82.30 billion, a P/E ratio of 18.71, a PEG ratio of 2.03 and a beta of 0.53. The business has a fifty day moving average price of $38.51 and a 200-day moving average price of $38.36.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's payout ratio is presently 77.78%.

Hedge Funds Weigh In On GSK

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rexford Capital Inc. purchased a new position in GSK during the second quarter worth about $245,000. SkyView Investment Advisors LLC purchased a new position in GSK during the second quarter worth about $303,000. Captrust Financial Advisors grew its position in GSK by 11.0% during the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company's stock worth $3,267,000 after buying an additional 8,432 shares in the last quarter. IHT Wealth Management LLC grew its position in GSK by 12.1% during the second quarter. IHT Wealth Management LLC now owns 14,736 shares of the pharmaceutical company's stock worth $566,000 after buying an additional 1,589 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S grew its position in GSK by 28.2% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company's stock worth $4,656,000 after buying an additional 26,685 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.